The international chronic myelomonocytic leukemia (CMML) treatment market is witnessing a period of steady growth. This development can be attributed to several factors, including the rising incidence of CMML, advancements in treatment, and growing awareness about the disease. The market is characterized by a varied range of medicines available, in